These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36711335)

  • 1. Posner-Schlossman syndrome relapse following inactivated COVID-19 vaccination in China.
    Sheng Q; Sun Y; Zhai R; Fan X; Ying Y; Kong X
    Front Public Health; 2022; 10():1051378. PubMed ID: 36711335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of 2% ganciclovir eye drops on cytomegalovirus positive Posner-Schlossman syndrome].
    Zhai RY; Xu H; Kong XM; Wang ZJ
    Zhonghua Yan Ke Za Zhi; 2018 Nov; 54(11):833-838. PubMed ID: 30440154
    [No Abstract]   [Full Text] [Related]  

  • 3. 2% Ganciclovir Controlled Posner-Schlossman Syndrome Relapse and Reduced the Chance of Corticosteroid Dependence: A Large Cohort in East China.
    Sheng Q; Sun Y; Zhai R; Fan X; Ying Y; Kong X
    Ocul Immunol Inflamm; 2024 Jul; 32(5):505-512. PubMed ID: 37437131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steroid-Dependency in Posner-Schlossman Syndrome: A Suggested Topical 2% Ganciclovir and Gradual Decrement of Topical Steroid Combination Therapy from Shanghai PSS Study.
    Ying Y; Sun Y; Sheng Q; Zhai R; Fan X; Kong X
    Ocul Immunol Inflamm; 2024 Jul; 32(5):513-519. PubMed ID: 37703505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term oral therapy with valganciclovir in patients with Posner-Schlossman syndrome.
    Sobolewska B; Deuter C; Doycheva D; Zierhut M
    Graefes Arch Clin Exp Ophthalmol; 2014 Jan; 252(1):117-24. PubMed ID: 24287937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2% Ganciclovir Eye Drops Control Posner-Schlossman Syndrome Relapses With/Without Cytomegalovirus Intraocular Reactivation.
    Sheng Q; Zhai R; Fan X; Kong X
    Front Med (Lausanne); 2022; 9():848820. PubMed ID: 35355609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of cases needing advanced treatment for intractable Posner-Schlossman syndrome.
    Maruyama K; Maruyama Y; Sugita S; Mori K; Yokoyama Y; Sanuki-Kunimatsu S; Nakagawa H; Kinoshita S; Mochizuki M; Nakazawa T
    BMC Ophthalmol; 2017 Apr; 17(1):45. PubMed ID: 28399831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk for uveitis relapse after COVID-19 vaccination.
    Zhong Z; Wu Q; Lai Y; Dai L; Gao Y; Liao W; Feng X; Yang P
    J Autoimmun; 2022 Dec; 133():102925. PubMed ID: 36209692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of inactivated COVID-19 vaccination in adult rheumatic patients in South China: a prospective study.
    Zeng H; Liu H; Liu Z; Zhou X; Lu X; Yan Z; Zhou Y; Dai L; Chen Y; Yang T; Yin Z; Ye Z
    Hum Vaccin Immunother; 2022 Nov; 18(5):2090176. PubMed ID: 35878733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes in cytomegalovirus-positive Posner-Schlossman syndrome patients treated with topical ganciclovir therapy.
    Su CC; Hu FR; Wang TH; Huang JY; Yeh PT; Lin CP; Wang IJ
    Am J Ophthalmol; 2014 Nov; 158(5):1024-1031.e2. PubMed ID: 25124264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter study of ocular inflammation after COVID-19 vaccination.
    Yasaka Y; Hasegawa E; Keino H; Usui Y; Maruyama K; Yamamoto Y; Kaburaki T; Iwata D; Takeuchi M; Kusuhara S; Takase H; Nagata K; Yanai R; Kaneko Y; Iwahashi C; Fukushima A; Ohguro N; Sonoda KH;
    Jpn J Ophthalmol; 2023 Jan; 67(1):14-21. PubMed ID: 36417027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Posner-Schlossman syndrome in Wenzhou, China: a retrospective review study.
    Jiang JH; Zhang SD; Dai ML; Yang JY; Xie YQ; Hu C; Mao GY; Lu F; Liang YB
    Br J Ophthalmol; 2017 Dec; 101(12):1638-1642. PubMed ID: 28450379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Analysis of Dynamic Changes and Prognosis of Posner-Schlossman Syndrome with Cytomegalovirus Infection and Antiviral Therapy.
    Sheng Q; Zhai R; Fan X; Kong X
    J Ophthalmol; 2021; 2021():6687929. PubMed ID: 34123414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Posner-Schlossman Syndrome European Study Group: study protocol and baseline patients characteristics of a multicentre study.
    Interlandi E; Cimino L; Accorinti M; Miserocchi E; Latanza L; Allegri P; Mora P; Fonollosa A; Adan A; Pavesio C; De Marco R; Gandolfi SA; Nucci P; De Luca M; Gozzi F; Visioli G; Rissotto F; Rissotto R; Bellucci C; Cachero JM; Pellegrini F; Li Calzi G; Sainz de la Maza M; Cirillo P; Mastrofilippo V; Sacchi M
    Br J Ophthalmol; 2024 May; ():. PubMed ID: 38811053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammatory ocular events after inactivated COVID-19 vaccination.
    Fei P; Feng H; Li J; Liu M; Luo J; Ye H; Zhao P
    Hum Vaccin Immunother; 2022 Nov; 18(6):2138051. PubMed ID: 36369840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different composition of intraocular immune mediators in Posner-Schlossman-Syndrome and Fuchs' Uveitis.
    Pohlmann D; Schlickeiser S; Metzner S; Lenglinger M; Winterhalter S; Pleyer U
    PLoS One; 2018; 13(6):e0199301. PubMed ID: 29944680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
    Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
    PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Characteristics of Posner-Schlossman Syndrome Patients in China.
    Gao T; Song S; Ke X; Li S; Zhang D; Chen X; Zhang C
    Biomed Res Int; 2023; 2023():4110344. PubMed ID: 36714029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
    Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
    Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.